Logo of Renerve (ASX:RNV)Latest Renerve (ASX:RNV) News

Page 2
Page 2 of 5

ReNerve Expands Asia-Pacific Reach with Philippines Marketing Approval

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.
Ada Torres
6 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

ReNerve Posts Record $211k Sales as Asia-Pacific Expansion Accelerates

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.
Ada Torres
29 July 2026

Market Wrap - Week 28 (6 July -> 10 July) 2026

Mining news drove the week, with drilling hits, funding wins and takeover bids pushing several small and mid-cap names sharply higher or lower. The biggest swings came from tin, platinum group metals and copper, while gold M&A in WA stayed at the centre of trading.
Logan Eniac
11 July 2026

Healthcare Wrap - Week 28 (6 July -> 10 July) 2026

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.
Logan Eniac
11 July 2026

ReNerve Secures A$5 Million Convertible Note Facility to Fuel US Expansion and Product Growth

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.
Ada Torres
9 July 2026

ReNerve Expands Into Indonesia With NervAlign Nerve Cuff Approval

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.
Ada Torres
6 July 2026

Healthcare Wrap - Week 24 (8 June -> 12 June) 2026

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.
Logan Eniac
13 June 2026

ReNerve Taps J4 to Boost Empliq Production Amid Rising Hospital Demand

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.
Ada Torres
11 June 2026

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.
Logan Eniac
6 June 2026

ReNerve Expands Asia-Pacific Reach with Malaysian Distribution Deal

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.
Ada Torres
5 June 2026

ReNerve Secures Exclusive Distribution Deal to Unlock 88 Million-Strong Greater Bay Area Market

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.
Ada Torres
1 June 2026